REFERENCES

- 1 Lavelle A, Sugrue R, Lawler G, *et al.* Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. *Eur Respir J* 2009; 34: 770–775.
- 2 Hoeper MM. Liver toxicity: the Achilles heel of endothelin receptor antagonist therapy? *Eur Respir J* 2009; 34: 529–530.
- 3 Nagai Y, Okada E, Mihara S, *et al.* Severe liver dysfunction due to bosentan in a patient with mixed connective tissue disease. *Eur J Dermatology* 2008; 18: 190–191.
- 4 Dwyer N, Jones G, Kilpatrick D. Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate. *J Clin Rheumatology* 2009; 15: 88–89.
- 5 Humbert M, Segal ES, Kiely DG, *et al.* Results of European post-marketing surveillance of bosentan in pulmonary hypertension. *Eur Respir J* 2007; 30: 338–344.

DOI: 10.1183/09031936.00160309

From the author:

I thank P.A. Corris and D. Langleben for their comments on my editorial [1] in which I have clearly indicated that: "...the possibility cannot be excluded that sitaxentan is afflicted with a higher potential of causing severe liver toxicity than the two other ERAs. As exact numbers are not available, and under-reporting may have occurred for any of the three drugs, there is not enough evidence to decide whether this conclusion is justified." This statement clearly is in line with the comments of P.A. Corris and D. Langleben who should be applauded for alerting us about further cases of severe liver toxicity

associated with the use of all three endothelin receptor antagonists, some of which have not been reported in the medical literature. The statement of P.A. Corris and D. Langleben that "every case of severe hepatotoxicity should be reported" does not seem to differ from the final conclusion of my editorial that "...liver monitoring should remain an integral part of ERA therapy. Physicians are urged to report all cases of serious liver injury potentially linked to these drugs..." This remains true for all three endothelin receptor antagonists.

M.M. Hoeper

Respiratory Medicine, Hannover Medical School, Hannover, Germany.

Correspondence: M.M. Hoeper, Respiratory Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, Germany. E-mail: hoeper.marius@mh-hannover.de

Statement of Interest: A statement of interest for M.M. Hoeper can be found at www.erj.ersjournals.com/misc/statements.dtl

REFERENCES

- 1 Hoeper MM. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? *Eur Respir J* 2009; 34: 529–530.

DOI: 10.1183/09031936.00166409